- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/54 - Interleukines [IL]
Détention brevets de la classe C07K 14/54
Brevets de cette classe: 4028
Historique des publications depuis 10 ans
|
119
|
157
|
205
|
233
|
335
|
356
|
349
|
407
|
422
|
371
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Immatics Biotechnologies GmbH | 1144 |
124 |
| Regeneron Pharmaceuticals, Inc. | 4448 |
83 |
| Xencor, Inc. | 395 |
60 |
| Altor BioScience, LLC | 76 |
58 |
| Immunitybio, Inc. | 480 |
57 |
| Board of Regents, The University of Texas System | 5947 |
46 |
| The Trustees of the University of Pennsylvania | 4378 |
41 |
| The Board of Trustees of the Leland Stanford Junior University | 6545 |
40 |
| Modernatx, Inc. | 1253 |
37 |
| Obsidian Therapeutics, Inc. | 78 |
34 |
| City of Hope | 1007 |
32 |
| National University of Singapore | 2517 |
32 |
| Memorial Sloan-Kettering Cancer Center | 1981 |
30 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2918 |
30 |
| Yale University | 2447 |
30 |
| Genentech, Inc. | 4005 |
29 |
| Deka Biosciences, Inc. | 42 |
29 |
| Cytune Pharma | 39 |
25 |
| The Regents of the University of California | 20296 |
24 |
| Janssen Biotech, Inc. | 1595 |
24 |
| Autres propriétaires | 3163 |